{"slug":"bronchogen","seoKey":"bronchogen","displayName":"Bronchogen","codes":["AEDL"],"synonyms":["Ala-Glu-Asp-Leu","AEDL peptide","H-Ala-Glu-Asp-Leu-OH","L-alanyl-L-glutamyl-L-aspartyl-L-leucine","Bronchogen / Бронхоген (Russian trade name)","AKS-B / АКС-Б (declared peptide complex of the Russian capsule)"],"legalClass":"research_chemical","identifiers":{"cas":"857267-12-0","pubchemCid":11690869,"inchikey":"OFZRHTIWKZWPQF-BJDJZHNGSA-N","formula":"C18H30N4O9","molecularWeight":446.5,"sequence":"AEDL"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and not registered as a substance. Federal queries on 2026-09-23 returned no match: no drug label, no approval record, no adverse event report, no entry in the labelling database and no record in the substance registration system, which is why there is no UNII. The only record matching the sequence there is human C-peptide, which contains it as a fragment. Control queries with an approved active ingredient returned hits in each interface. The substance has also never been nominated for the compounding bulks list, whose full text was searched with a working control.","source":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22Bronchogen%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no INN and no ATC code. The agency's search could not be read on 2026-09-23 because it returned HTTP 403, so this is a negative finding drawn from the absence of any name, code or approval in every other register checked and from the lapse of the only European patent, EP 1758922.","source":"https://www.ema.europa.eu/en/search?search_api_fulltext=bronchogen"},{"market":"DE","status":"not_approved","note":"Neither a national nor an EU marketing authorisation exists; this follows from the European finding, not from a separate register query. An injectable preparation is therefore an unapproved medicinal product and may not be imported or dispensed. Disease claims made by Russian sellers for bronchitis, asthma or chronic obstructive lung disease have no approval behind them. The substance is not named in the schedule to the Anti-Doping Act, whose growth factor section is a closed list; the full text was checked on 2026-09-23. Sporting rules are unaffected by that.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register was not queried on 2026-09-23, because its search is script-driven and did not return readable results for neighbouring substances. This negative finding therefore rests on the absence of any approval elsewhere and on the absence of any clinical development, not on a register confirmation.","source":"https://products.mhra.gov.uk/search/?search=bronchogen"},{"market":"AU","status":"not_approved","note":"No marketing authorisation known. The register of therapeutic goods did not respond on 2026-09-23, so no entry could be confirmed or ruled out directly. This negative finding rests on the absence of any approval elsewhere. Peptides without a register entry are unapproved therapeutic goods.","source":"https://www.tga.gov.au/resources/artg?keywords=bronchogen"},{"market":"CA","status":"not_approved","note":"No drug identification number and no natural product number. The drug product database returned empty results for the trade name and the ingredient name on 2026-09-23, and so did the natural health products database, while a control query for an authorised product returned its identification number.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=bronchogen"},{"market":"CH","status":"not_approved","note":"Not authorised. The full list of authorised human medicine packs was downloaded and searched on 2026-09-23 with no entry for the trade name, while control searches for an authorised product and its active ingredient returned hits.","source":"https://www.swissmedic.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/11690869"],"lastVerified":"2026-09-24","version":"1.0","published":true,"locale":"en","title":"Bronchogen: what the studies show, status and safety","summary":"Bronchogen is a synthetic chain of four amino acids, Ala-Glu-Asp-Leu, from a St Petersburg institute, sold as a lung peptide. Unusually for this series, the lung label holds up: the inventors' patent describes three lung-injury models in 336 rats, and an outside pulmonology institute reported airway findings in rats. No study in people has ever been registered or published. It is approved as a medicine nowhere, and Russia sells it only as an oral food supplement.","updated":"2026-09-24","url":"https://mypep.app/peptides/bronchogen"}